8-K: Theriva Biologics' VCN-01 Shows Promise in Pancreatic Cancer

Theriva Biologics announced positive expanded Phase 2b VIRAGE trial data for VCN-01 in metastatic pancreatic cancer and upcoming presentations at medical conferences.

Summary

• Theriva Biologics will present expanded metastatic pancreatic ductal adenocarcinoma (mPDAC) data from the VIRAGE Phase 2b trial for VCN-01 at the ESMO 2025 Annual Congress on October 20, 2025.
• The VIRAGE trial, involving 112 randomized patients, evaluated VCN-01 in combination with gemcitabine/nab-paclitaxel (GA) standard of care chemotherapy.
• In the full analysis set (FAS) population, patients receiving VCN-01 + GA showed an overall survival (OS) of 10.8 months compared to 8.6 months for GA alone (HR 0.57; P=0.055).
• Progression-free survival (PFS) in the FAS population was 7.0 months for VCN-01 + GA versus 4.6 months for GA alone (HR 0.55; P=0.011).
• Duration of response (DoR) was significantly improved in both mITT and FAS populations, with 11.2 months for VCN-01 + GA compared to 5.4 months for GA alone (HR 0.22; P=0.004).
• Objective response rate (ORR) in the FAS population was 39.6% for VCN-01 + GA versus 31.3% for GA alone.
• A subgroup analysis of patients receiving two VCN-01 doses and starting GA cycle 4 showed greater improvement in OS (14.8 vs 11.6 months; HR 0.44; P=0.046) and PFS (11.2 vs 7.4 months; HR 0.48; P=0.017).
• VCN-01 administration was well tolerated, with all 13 VCN-01-related serious adverse events resolved; common side effects included flu-like symptoms (13.2%), transaminase increase (5.7%), and drug-induced liver injury (3.8%).
• The study met its primary endpoints, demonstrating improved OS, PFS, and DoR for patients receiving VCN-01 + GA compared to GA standard of care.
• A separate poster presentation on previously reported blinded safety and pharmacokinetic data for SYN-004 (ribaxamase) in allogeneic hematopoietic transplant recipients will occur at IDWeek 2025 on October 20, 2025.

Sentiment

Score: 8

Explanation: The filing reports positive Phase 2b clinical trial results for VCN-01 in metastatic pancreatic cancer, a disease with high unmet medical need. The data shows improved overall survival, progression-free survival, and duration of response, along with a well-tolerated safety profile. This represents a significant step forward for the company's lead candidate.

Positives

• VCN-01 + GA demonstrated improved overall survival (OS) of 10.8 months in the FAS population compared to 8.6 months for GA alone, meeting the trial's primary endpoint for OS in this population (P=0.055, designed with alpha 0.1).
• Significant improvement in progression-free survival (PFS) was observed in the FAS population (7.0 months vs. 4.6 months; HR 0.55; P=0.011).
• Duration of response (DoR) was substantially extended to 11.2 months for VCN-01 + GA compared to 5.4 months for GA alone (HR 0.22; P=0.004).
• A specific subgroup analysis showed even greater improvements in OS (14.8 vs 11.6 months; HR 0.44; P=0.046) and PFS (11.2 vs 7.4 months; HR 0.48; P=0.017) for patients receiving two VCN-01 doses.
• VCN-01 administration was well tolerated, with all 13 VCN-01-related serious adverse events resolving.
• The study successfully met its primary endpoints, indicating a positive outcome for the VCN-01 trial.

Negatives

• The overall survival (OS) P-value in the modified intent to treat (mITT) population was 0.196, which did not meet the trial's specified alpha of 0.1 for statistical significance.

Risks

• The press release includes safe harbor language indicating that certain statements are forward-looking and subject to risks and uncertainties, rather than historical facts.

Future Outlook

The company is focused on advancing its clinical-stage candidates, VCN-01 and SYN-004, with upcoming presentations of positive data at major medical conferences, suggesting continued development and potential for these therapeutics in areas of high unmet need.

Industry Context

The positive Phase 2b data for VCN-01 in metastatic pancreatic cancer positions Theriva Biologics favorably in the competitive oncology landscape, particularly in the challenging area of pancreatic cancer treatment where new therapeutic options are urgently needed. Oncolytic adenoviruses like VCN-01 represent an innovative approach to cancer therapy, combining direct tumor lysis with immune system activation and enhanced chemotherapy delivery. The SYN-004 data addresses the critical issue of gut microbiome preservation in transplant recipients, a growing area of focus in infectious diseases and supportive care.

Stakeholder Impact

• Shareholders may see increased confidence and potential appreciation in stock value due to positive clinical trial results for a key therapeutic candidate.
• Patients with metastatic pancreatic cancer could benefit from a new, effective, and well-tolerated treatment option if VCN-01 continues to advance through clinical development.
• The medical community will gain new insights into the efficacy and safety of VCN-01 and SYN-004 through upcoming presentations at major conferences.

Next Steps

• Presentation of expanded VCN-01 mPDAC data at the ESMO 2025 Annual Congress on October 20, 2025.
• Poster presentation of SYN-004 interim safety and pharmacokinetic data at IDWeek 2025 Annual Meeting on October 20, 2025.

Key Dates

Recommendation

The positive Phase 2b results for VCN-01 in metastatic pancreatic cancer, a notoriously difficult-to-treat disease with high unmet need, are highly encouraging. The demonstrated improvements in overall survival, progression-free survival, and duration of response, coupled with a favorable safety profile, suggest significant therapeutic potential. While the OS P-value in the mITT population was not statistically significant, the FAS population OS met the trial's alpha threshold, and other key efficacy endpoints were strongly positive. This data significantly de-risks the VCN-01 program and positions Theriva Biologics for potential future success, making it an attractive investment for long-term growth.

Keywords

Theriva Biologics, TOVX, VCN-01, Pancreatic Cancer, mPDAC, VIRAGE trial, Oncolytic Adenovirus, SYN-004, Ribaxamase, aGVHD, HCT, ESMO 2025, IDWeek 2025, Clinical Trial Results